| abstract |
Chemically modified human growth hormone (rhGH) prepared by adding a transient linker comprising polyethylene glycol. The chemically modified protein has a longer duration of rhGH activity than unmodified rhGH, thereby enabling lower doses and administration opportunities, and the modified rhGH does not cause lipoatrophy. The invention also includes methods of use for the treatment and/or prevention of diseases or disorders in which the use of growth hormone is beneficial. |